Invivyd (IVVD) has released its Q1 2026 numbers with revenue of about US$13.7 million and a basic EPS loss of US$0.13, alongside a trailing 12 month net loss of US$77.6 million. The company has seen revenue move from US$25.4 million in Q4 2024 on a trailing 12 month basis to US$55.9 million in the latest trailing period, while trailing basic EPS has shifted from a loss of US$1.43 to a loss of US$0.35. Investors are therefore looking at a business where top line momentum is meeting still heavy but shrinking losses and compressed margins.

See our full analysis for Invivyd.

With the headline results on the table, the next step is to see how these margins and growth trends compare with the widely held narratives around Invivyd's long term prospects and risk profile.

Losses remain heavy at US$41.4m this quarter

• For Q1 2026, Invivyd reported a net loss of US$41.4 million on US$13.7 million of revenue, compared with a loss of US$11.07 million on US$17.2 million of revenue in Q4 2025, and on a trailing 12 month basis the company reported a total net loss of US$77.6 million.
• Bears point out that the business is still unprofitable over the trailing 12 months and is not forecast to reach profitability in the next three years, and this quarter's loss profile lines up with that concern.
  • Even though losses have been reduced at an average rate of 22.8% per year over the past five years, the latest quarter's US$41.4 million loss sits well above the trailing 12 month loss of US$77.6 million, so short term earnings are still heavily in the red.
  • Critics also highlight that revenue is expected to grow quickly, at about 46% per year based on the supplied forecasts, which means bears are focused less on top line potential and more on how long these losses might continue to weigh on the business.

Skeptics argue that heavy quarterly losses and ongoing unprofitability could limit how much value investors are willing to assign to future growth, so it is worth reading how that case is built out in more detail in the 🐻 Invivyd Bear Case.

Rapid revenue growth forecasts meet past loss reduction trend

• Over the last year, trailing 12 month revenue has moved from US$25.4 million to US$55.9 million, while the trailing loss has moved from US$169.9 million to US$77.6 million, which lines up with the reported 46% annual revenue growth forecast and the 22.8% per year reduction in losses over the past five years.
• Bullish investors argue that this combination of strong revenue growth expectations and historic loss reduction could support a stronger long term profile than the headline Q1 loss suggests.
  • The outlook pointing to about 46% revenue growth per year and the five year history of losses shrinking at 22.8% per year heavily supports the idea that the business model has already moved a long way from the US$169.9 million trailing loss seen a year ago.
  • At the same time, the fact that the company is still loss making on US$55.9 million of trailing revenue shows why bulls see an opportunity for future margin improvement, while more cautious investors focus on how long that improvement might take to show up in reported EPS.

Supporters of the bullish view point to the combination of faster revenue growth and shrinking historical losses as the core of their thesis, and you can see how that story is laid out in full in the 🐂 Invivyd Bull Case.

P/S of 6.1x plus DCF fair value of US$100.37 create a wide valuation gap

• Invivyd is trading on a P/S of 6.1x compared with a US Biotechs industry average of 10.9x and a peer average of 20.4x, while the supplied DCF fair value of US$100.37 sits a long way above the current share price of US$1.21.
• Consensus narrative watchers highlight that this mix of lower P/S and a DCF fair value far above the current price makes valuation look appealing on paper, but they also point back to ongoing losses and recent dilution as reasons the stock might still be priced cautiously.
  • The trailing 12 month loss of US$77.6 million and forecasts for continued unprofitability over at least the next three years help explain why the market is not pricing Invivyd closer to either the 10.9x industry P/S or the DCF fair value of US$100.37.
  • Recent shareholder dilution is flagged as a major risk because it affects per share metrics and potential investor returns, which can offset some of the apparent upside that a lower 6.1x P/S and a high modeled fair value might suggest.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Invivyd on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between concern about risks and optimism about potential rewards, it makes sense to review the data yourself and move quickly while opinions are forming by weighing up the 4 key rewards and 3 important warning signs.

Explore Alternatives

Invivyd's ongoing heavy losses, continued unprofitability over the next few years, and recent shareholder dilution highlight meaningful risk for investors focused on stability.

If you want ideas that aim to keep downside in check, compare this profile with companies in our 66 resilient stocks with low risk scores today while the market is still sorting the standouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.